Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2023-01-25 Director's Dealing
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-01-25 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Enveric Biosciences, Inc. It registers shares of common stock reserved under the company's 2020 Long-Term Incentive Plan. The text includes detailed information about the plan, share adjustments due to a reverse stock split, and incorporation by reference of other SEC filings such as 10-K and 10-Q reports. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans. This is a capital markets filing related to share issuance under an employee plan, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including registration of shares for employee plans.
2023-01-20 English
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-14 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 28, 2022, reporting the submission of matters to a vote of security holders at the company's 2022 annual meeting. It details the voting results for director elections, advisory vote on executive compensation, and ratification of the independent auditor. The document references the definitive proxy statement filed earlier but does not contain the proxy statement itself. The content is focused on official voting results from the annual meeting, which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4820 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2022-10-28 English
Investor Presentation 2022
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 23, 2022, by Enveric Biosciences, Inc. The key content described includes an investor presentation (Exhibit 99.1) and a press release (Exhibit 99.2). The text explicitly states that the investor presentation is attached and is intended for distribution to the investment community, including at conferences. There is no detailed financial data or comprehensive report content within the text itself, only references to attached exhibits. The primary purpose of this filing is to furnish an investor presentation and a press release, not to provide a full financial report or earnings release. According to the filing definitions, an investor presentation is classified as IP. The document length is just over 5,000 characters, but the content is clearly an investor presentation attached to a Form 8-K. Therefore, the correct classification is Investor Presentation (IP).
2022-10-24 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It specifically mentions adding a letter from the former independent registered public accounting firm as an exhibit. The content focuses on an amendment to a current report and includes a letter from the auditor, not a full audit report or annual report. The document length is short (3486 characters), and it serves to amend and provide additional information to a prior filing rather than presenting comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-10-06 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.